Roche Holdings AG's RHHBY market capitalization grew by 13.8%, spurred by the FDA’s approval of two key products, Ocrevus Zunovo for multiple sclerosis and Tecentriq Hybreza for oncology indications, ...

Roche's key products like Vabysmo, Ocrevus, and Phesgo are performing well. Read why RHHBY stock looks well positioned to ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today reported its financial and operating results ...

A new version called “Ocrevus Zunovo” was recently approved by the Food and Drug Administration and is reportedly much quicker to inject. “Not everybody has the luxury of being able to spend ...

Dubbed Ocrevus Zunovo, the under-the-skin version of the blockbuster CD20 antibody drug could represent an additional CHF 2 billion sales opportunity, Graham said during the investor call.

(WRIC) – The University of Virginia’s (UVA) health system has become one of the first in the country to administer a groundbreaking FDA-approved drug, Ocrevus Zunovo, to patients with ...

“In the quarter, the announcement of two highly anticipated partner approvals in the U.S. for Roche’s TECENTRIQ HYBREZA and OCREVUS ZUNOVO reinforces ENHANZE’s track record of 100% phase 3 ...

Over the last 7 days, the United States market has dropped 1.6%, yet it remains up by an impressive 30% over the past year, with earnings forecasted to grow by 15% annually. In this dynamic ...